Jennifer Hibma - Concepedia

Author

Jennifer Hibma

Pfizer (United States)ORCID

Also Known As

J.J. Hibma, Jennifer E. Hibma, Jennifer Hibma

Publications

276

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)

About

Jennifer Hibma is an author at Pfizer (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	103
2	Pharmacology	3	3	103
3	Health Sciences	1	1	25
4	Biochemistry	1	1	57
5	Pathology	1	1	25

Jennifer Hibma

Publications

188

Citations

H-Index

Page 1

	Year	Citations
The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin Jennifer Hibma, Arik A. Zur, Richard A. Castro, Clinical Pharmacokinetics Pharmacological StudyBiochemistryMedicineMechanism Of ActionPharmacotherapy	2015	57
Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin Luke Fostvedt, Jennifer Hibma, Joanna C. Masters, Clinical Pharmacology & Therapeutics	2019	32
Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer Joseph Chen, Ana Ruiz-Garcı́a, Leonard P. James, Clinical Pharmacology & Therapeutics Cancer ManagementPathologySupport Benefit–risk AssessmentHematological MalignancyMetronomic Therapy	2021	25
Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia Jennifer Hibma, Beverly Knight Clinical Pharmacokinetics Hematological MalignancyOncologyPharmacokinetic ModelingGemtuzumab OzogamicinMixed-phenotype Acute Leukemia	2018	21
Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib Ana Ruiz-Garcı́a, Weiwei Tan, Jerry Li, Pharmaceutics	2020	16
Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc‐concentration modelling Jennifer Hibma, Hagop M. Kantarjian, Daniel J. DeAngelo, British Journal of Clinical Pharmacology	2018	14
Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma Mohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, Blood	2022	12
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants Jennifer Hibma, Melissa O’Gorman, Sunil Nepal, Cancer Chemotherapy and Pharmacology	2021	11

Page 1